Securing Real-World Evidence (RWE) through Phase 4 Clinical Trial and Accelerating Market Penetration

Kuros Biosciences AG (KURN) is actively conducting the 'PRECISE' Phase 4 clinical trial (NCT05037968) to solidify the clinical benefits of its synthetic bone graft extender, 'MagnetOs Flex Matrix.' This study represents a strategic effort to generate substantial real-world evidence (RWE) for a product that has already received 510(k) approval from the U.S. Food and Drug Administration (FDA) and has been launched in the market. The trial, involving 100 patients, aims for a primary completion date of December 1, 2026, and seeks to gain the trust of key opinion leaders (KOLs) in real-world surgical settings to maximize prescription rates. In the medical device market, RWE serves as a critical indicator that directly impacts the expansion of insurance coverage criteria and the entry into new hospitals, making it highly significant from a business perspective.

Enhancing Bed Surface Science Technology and Autograft Fusion

MagnetOs Flex Matrix goes beyond simply acting as a physical barrier; it is a next-generation synthetic bone graft extender that incorporates the unique NeedleGrip surface technology. This micro-structured surface induces immunomodulation in vivo, promoting the polarization of M2 macrophages, which are beneficial for bone formation. In this clinical trial, the product will be administered in a 1:1 volume ratio with the patient's autograft, acting as a powerful adjunct to simultaneously enhance structural stability at the surgical site and promote bone regeneration. Through this, Kuros aims to clearly demonstrate its technological differentiation, providing high fusion rates without the need for cell extraction to surgeons.

Direct Comparison with High-Cost Cell-Based Allograft, Trinity ELITE

A key aspect of this trial is the head-to-head comparison with 'Trinity ELITE,' a high-cost, cell-based allograft from Orthofix Medical Inc. (OFIX) and MTF Biologics. Trinity ELITE contains active cells extracted from actual human tissue, providing excellent bone-forming capabilities, but it has the limitation of extremely high harvesting and storage costs. In contrast, MagnetOs is a chemically synthesized product, offering significant advantages in terms of distribution costs and ease of handling. If this Phase 4 trial demonstrates that MagnetOs has comparable or superior fusion efficacy to this expensive cell-based product, the market landscape will undoubtedly shift rapidly towards synthetic products.

Paradigm Shift in Spinal Fusion Market and Creation of Economic Value

Patients in the trial are those who require instrumented posterolateral fusion for up to four levels due to degenerative disc disease. As the global population ages, the market size for spinal fusion bone graft substitutes is expected to reach approximately USD 3.98 billion (approximately 5.3 trillion KRW) by 2026, maintaining a steady growth trend. With increasing pressure to reduce costs in the healthcare setting, the demand for affordable, standardized, high-performance synthetic products is rapidly increasing. Therefore, if Kuros succeeds in this trial, it is expected to revolutionize existing complex and expensive treatment protocols and redefine industry standards.